The dhr was reviewed for lot 21c1149 and indicated no abnormal processing.The lot in question met all specifications prior to its release.There have been no ncrs or capas associated with this lot.Cerapedics risk analysis document ra-001, revision 23 (putty) was reviewed.The failure mode identified in this complaint is already identified under line item 38 (potential effect 2) - "inadequate retention in graft site, migration." therefore, no updates to the risk assessment are required.There have been 8 (eight) previous complaints related to this potential failure mode.Based on the total number of units distributed (n=265,783), the observed rate is 0.003%.The mitigated risk probability for this potential failure mode is estimated to be 1 or an estimated occurrence rate of 0.01%.Therefore, the benefit-risk analysis remains unchanged.Us putty ifu (p/n 40002-07-4) lists the following as a potential adverse effect: "extrusion or migration of the i-factor peptide enhanced bone graft, as is possible with any bone graft, resulting in pain, neural impingement, physical impairment, or loss of function; any of which may require revision surgery." as such, no updates are required for the ifu.
|